XRHealth Reports Clinical Trial Finds that Virtual Reality Therapy May Serve as Effective Adjunct To Anesthesia For Surgical Procedures

New Study Published in PLOS ONE Highlights Clinical Trial Findings; XRHealth Virtual Reality Therapy Aided Intraoperative Control of Pain and Anxiety without Intravenous Anesthetics

The results of a clinical trial using software from XRHealth, developer and operator of virtual treatment rooms in the metaverse,  published in PLOS ONE demonstrated that virtual reality therapy may serve as an effective adjunct to anesthesia for surgical procedures. The trials were conducted with XRHealth’s immersive virtual reality software.

The clinical trial consisted of 34 patients undergoing hand and wrist surgery. All of the patients were given a peripheral nerve block before surgery.  Patients were randomized to intraoperative immersive virtual reality with intravenous anesthesia only given as needed, or to usual care as directed by the anesthesiologist. The VR therapy software provided an immersive, engaging environment that guided patients through relaxation and pain reduction techniques while undergoing the surgery.

The results of the trial showed that the majority of patients (13/17) using the XRHealth VR technology did not need any intravenous sedatives during surgery. A postoperative survey demonstrated similarly low levels of pain and anxiety for patients in both control groups.  Other secondary findings demonstrated that patients using the VR technology recovered from anesthesia more quickly and left the recovery room earlier than those in the usual care group.

“Anesthesia providers are always trying to balance the primary interests of patient comfort and patient safety.  Our results demonstrate that VR may help provide satisfactory control of pain and anxiety for procedures such as upper extremity surgery with regional anesthesia,” says senior study author Brian O’Gara, MD MPH, Principal Investigator at Beth Israel Deaconess Medical Center. “This is incredibly valuable in that VR may allow for avoidance of risky sedatives without detracting from the patient experience.  If the use of this technique can also aid perioperative efficiency, it has the potential to be a real game-changer for both patients and providers.”

These findings could lead to a discussion in the medical industry about using non-pharmaceutical interventions during surgical procedures that both enhance the patient experience during surgery and provide a better postoperative recovery.

“Transporting patients to different treatment rooms in the metaverse while undergoing operations in the real world can provide significant medical breakthroughs in the healthcare industry; managing pain and anxiety in a virtual environment can be a game changer for coping through surgical procedures and will  help the patients’ body heal faster eliminating the recovery from the anesthesia,” says Eran Orr, CEO of XRHealth.

The BIRD Foundation granted XRHealth and Beth Israel Deaconess Medical Center $900K to conduct clinical trials investigating whether immersive VR can reduce sedative requirements and improve patient satisfaction during knee replacement surgery, and improve the quality of recovery from bariatric surgery.

SourceXRHealth
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.
“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  
Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s Transpose® RT cell therapy system.
Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces outstanding 12-month data from its first-in-human...

By using this website you agree to accept Medical Device News Magazine Privacy Policy